共 16 条
- [1] Sigler K.A., Guernsey B.G., Ingrim N.B., Buesing A.A., Effect of triplicate prescription law on prescribing of schedule II drugs, Am J Hosp Pharm, 42, (1985)
- [2] Weintraub M., Singh S., Byrne L., Maharaj K., Guttmacher L., Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations, JAMA, 266, (1991)
- [3] Zullich S.G., Grasela T.H., Fiedler-Kelly J.B., Gengo F.M., Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities, Ann Pharmacother, 26, (1992)
- [4] Cooper J.R., Czechowicz D.J., Peterson R.C., Molinari S.P., Prescription drug diversion control and medical practice, JAMA, 268, (1992)
- [5] Glass R.M., Benzodiazepine prescription regulation: autonomy and outcome, JAMA, 266, (1991)
- [6] Stimmel B., Pain, Analgesia and Addiction: The Pharmacologic Treatment of Pain, (1983)
- [7] Khojasteh A., Evans W., Reynolds R.D., Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation, J Clin Oncol, 5, (1987)
- [8] Jasinski D.R., Assessment of the abuse potentiality of morphinelike drugs, Handbook of Experimental Pharmacology, (1977)
- [9] Roberts J., In Focus, Emerg Med News, 6, pp. 3-5, (1992)
- [10] Crews J.C., Denson D.D., Recovery of morphine from a controlled-release preparation, Cancer, 66, (1990)